Kenya: New HIV Prevention Injection Arrives in Kenya

18 February 2026
Capital FM (Nairobi)
By Davis Ayega

Nairobi — The first shipment of Lenacapavir, a new HIV prevention treatment, landed in the country on Tuesday night.

The delivery was confirmed by the US Embassy Nairobi, which said the medicine could sharply reduce new HIV infections, especially among pregnant and breastfeeding women, who remain among the most vulnerable.

"Lenacapavir is a game-changing HIV prevention treatment," the Embassy said.

Lenacapavir is different from existing HIV prevention options.

Instead of taking daily pills, people only need two injections a year to stay protected.

The drug is manufactured by Gilead Sciences, an American pharmaceutical company known for developing HIV treatments.

The U.S. government, working together with the Global Fund, has committed to co-funding the purchase of Lenacapavir for up to 2 million people worldwide, including those in Kenya.

Read the original article on Capital FM.

Tagged:
Copyright © 2026 Capital FM. All rights reserved. Distributed by AllAfrica Global Media (allAfrica.com). To contact the copyright holder directly for corrections — or for permission to republish or make other authorized use of this material, click here.

AllAfrica publishes around 600 reports a day from more than 90 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.